Home > News > Starpharma Initiates NIH-funded Human Trial for VivaGel
August 24th, 2006
Starpharma Initiates NIH-funded Human Trial for VivaGel
Abstract:
Starpharma Holdings Limited (ASX:SPL, USOTC:SPHRY) today announced the commencement of a Phase I safety trial in men for its lead product VivaGel™ (SPL7013 Gel) following successful review by the US Food and Drug Administration (FDA), local ethics committees, and the U.S. National Institutes of Health (NIH).
Source:
pharmalive.com
Bookmark:
Investments/IPO's/Splits
Harris & Harris Group Notes the Sale of a Second D-Wave Quantum Computer May 16th, 2013
Nanometrics Announces Upcoming Investor Events May 14th, 2013
Nanostart-holding New Asia Investments invests in breakthrough water projects May 13th, 2013
Harris & Harris Group Reports Financial Statements as of March 31, 2013 May 10th, 2013
Nanomedicine
Nanotechnology could help fight diabetes: Injectable nanogel can monitor blood-sugar levels and secrete insulin when needed May 16th, 2013
Nanobiotix Revenue for the 1st quarter of 2013 May 15th, 2013
Pitt Chemists Demonstrate Nanoscale Alloys So Bright They Could Have Potential Medical Applications: “Think about a particle that will not only help researchers detect cancer sooner but be used to treat the tumor, too.” May 15th, 2013
Using clay to grow bone: Researchers use synthetic silicate to stimulate stem cells into bone cells May 15th, 2013
Announcements
Artificial Forest for Solar Water-Splitting: Berkeley Lab Researchers Report First Fully Integrated Artificial Photosynthesis Nanosystem May 17th, 2013
Moth-Inspired Nanostructures Take the Color Out of Thin Films May 17th, 2013
NIA Public Briefing: Nanotechnology and the Council of Europe May 17th, 2013
Scientists capture first direct proof of Hofstadter butterfly effect May 17th, 2013